{
      "Rank": 141,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "transendocardial injection of placebo solution",
            "transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle."
      ],
      "ArmGroupInterventionName": [
            "Other: placebo intervention",
            "Other: bone marrow-derived MSCs injection"
      ],
      "ArmGroupLabel": [
            "placebo comparator",
            "bone marrow-derived MSCs injection"
      ],
      "ArmGroupType": [
            "Placebo Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01957826"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to assess the safety, the feasibility and the efficacy of transendocardial injection of bone marrow-derived mesenchymal stem cells (MSCs) in patients with dilated idiopathic cardiomyopathy."
      ],
      "BriefTitle": [
            "Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy"
      ],
      "CentralContactEMail": [
            "rsanzruiz@hotmail.com"
      ],
      "CentralContactName": [
            "Ricardo Sanz, MD",
            "Francisco Fernandez Avil\u00e9s, MD"
      ],
      "CentralContactPhone": [
            "034 91 426 5882"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER_GOV"
      ],
      "CollaboratorName": [
            "Ministerio de Sanidad, Servicios Sociales e Igualdad"
      ],
      "CompletionDate": [
            "March 2018"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Primary Idiopathic Dilated Cardiomyopathy"
      ],
      "ConditionAncestorId": [
            "D000006331",
            "D000002318",
            "D000006332",
            "D000083083",
            "D000030342"
      ],
      "ConditionAncestorTerm": [
            "Heart Diseases",
            "Cardiovascular Diseases",
            "Cardiomegaly",
            "Laminopathies",
            "Genetic Diseases, Inborn"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "All",
            "BC16",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "All Conditions",
            "Diseases and Abnormalities at or Before Birth",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Cardiomyopathy",
            "Idiopathic Dilated Cardiomyopathy",
            "Dilated Cardiomyopathy",
            "Idiopathic Dilated Cardiomyopathy"
      ],
      "ConditionBrowseLeafId": [
            "M11306",
            "M4719",
            "M8571",
            "M8572",
            "M2393",
            "M22839",
            "T1876",
            "T1877"
      ],
      "ConditionBrowseLeafName": [
            "Cardiomyopathies",
            "Cardiomyopathy, Dilated",
            "Heart Diseases",
            "Cardiomegaly",
            "Laminopathies",
            "Genetic Diseases, Inborn",
            "Dilated Cardiomyopathy",
            "Dilated Cardiomyopathy 1A"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000009202",
            "D000002311"
      ],
      "ConditionMeshTerm": [
            "Cardiomyopathies",
            "Cardiomyopathy, Dilated"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Chronic congestive heart failure (CHF) is a public health problem that entails high rates of morbidity and mortality, and enormous costs for health systems worldwide. In the United States there are 5 million people living with CHF, and each year 60.000 people reach terminal phases of the disease, with mortality rates of 70-80% at two years. Although the first cause of CHF in developed countries is atherosclerotic coronary artery disease (CAD), dilated idiopathic cardiomyopathy (DCM) represents almost half of the cases of newly diagnosed CHF. Treatment of CHF includes pharmacological and non-pharmacological strategies, including implantable cardioverter defibrillators, cardiac resynchronization therapy and heart transplantation. Despite all these advances, CHF prognosis remains poor. Cardiac stem cell therapy emerged more than ten years ago as a new hope for CHF patients.\n\nAlthough the most extensive evidence of the benefits of stem cell therapy for cardiovascular diseases refers to ischemic heart disease (CAD), initial experiences with stem cells for other conditions such as DCM are encouraging.\n\nThis randomized clinical trial will include 70 patients with DCM, left ventricular ejection fraction (LVEF) between 20% and 45%, and who are symptomatic in New York Heart Association (NYHA) functional class II-III/IV. In a first-in-man pilot phase, 10 patients will be treated with transendocardial injections of bone marrow-derived MSCs after cardiac catheterization and NOGA XPTM mapping of the left ventricle. A Data and Safety Monitoring Board (DSMB) will analyse the safety and feasibility of this first phase of the trial, and then 60 patients more will be randomized to receive MSCs or placebo (ratio 3:1).\n\nPrimary objectives include safety and feasibility variables, and secondary objectives include efficacy variables. All patients will be studied with a complete cardiac imaging protocol that includes: electrocardiography, echocardiography, treadmill tests with oxygen consumption, holter, laboratory analyses, magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), electromechanical mapping (NOGA XPTM) and quality of life questionnaires."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nII-III NYHA functional class, under optimal medical therapy.\nLVEF \u2265 20% and \u2264 45% by echocardiography, SPECT or left ventriculogram one month prior to enrollment.\nAnterior wall thickness \u2265 8 mm by echocardiography or MRI one month prior to enrollment.\nIdiopathic DCM diagnosis (having excluded CAD, valvular heart disease, cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases) six months prior to enrollment.\nPatients rejected for heart transplantation should have been discussed in the Heart Team at their respective centres, and a document stating the reason for exclusion will be kept in the medical record.\nAble to exercise on a treadmill, MVO2 between \u2265 12 and \u2264 21 ml/Kg/min.\nHemodynamic stability (blood pressure > 100/40 mmHg, heart rate < 110 bpm and oxygen saturation > 95%).\nNegative pregnancy test in women.\nSigned informed consent\n\nExclusion Criteria:\n\nEvidence of secondary dilated cardiomyopathy causes: CAD, valvular heart disease, cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases, myocarditis or postpartum ventricular dysfunction.\nPermanent atrial fibrillation.\nCandidates for ICD or CRT devices. Patients with theses devices can be enrolled if the device has been implanted at least 6 months before inclusion, and only if no-response has been observed to CRT.\nCandidates for heart transplantation if surgery is anticipated in the next 2 years.\nLeft ventricular thrombus by echocardiography, MRI or left ventriculogram.\nPeripheral artery disease that precludes cardiac catheterization with 8 Fr sheaths. .\nAnterior wall thickness < 8 mm by echocardiography or MRI one month prior to enrollment.\nChronic renal failure (creatinine > 2,5 mg/dL).\nI or IV NYHA functional class. Cardiogenic shock is defined as systolic blood pressure < 90 mmHg with no response to fluids, or < 100 mmHg with inotropes and without bradycardia.\nPrevious history of drug abuse (alcohol, etc\u2026).\nAcute or chronic infectious disease (including B/C hepatitis and HIV).\nPregnancy or child-bearing period.\nMRI contraindications: pacemakers, ICD, metalic prosthesis, etc.\nBleeding or coagulation disorders (INR > 2 without anticoagulation treatment).\nCancer history 5 years prior to enrollment.\nLife expectancy less than 1 year.\nAny disease or condition that the investigator finds decisive for exclusion"
      ],
      "EnrollmentCount": [
            "70"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "bone marrow-derived MSCs injection",
            "placebo comparator"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.",
            "placebo administration"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "bone marrow-derived MSCs injection",
            "placebo intervention"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Other",
            "Other"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "mesenchymal",
            "stem cells",
            "transendocardial injection",
            "dilated idiopathic cardiomyopathy",
            "idiopathic cardiomyopathy"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "November 18, 2016"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "November 17, 2016"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Hospital General Universitario Gregorio Mara\u00f1on"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Madrid",
            "Valladolid"
      ],
      "LocationContactEMail": [
            "rsanzruiz@hotmail.com"
      ],
      "LocationContactName": [
            "Ricardo Sanz, MD",
            "\u2022 Francisco Fernandez Aviles, PhD",
            "Ricardo Sanz, MD",
            "Francisco Fern\u00e1ndez-Avil\u00e9s, PhD",
            "Pedro Luis S\u00e1nchez, MD",
            "Mar\u00eda Eugenia Fern\u00e1ndez, PhD",
            "Enrique Guti\u00e9rrez, MD",
            "Esther P\u00e9rez, MD",
            "Adolfo Villa, MD",
            "Javier Anguita, MD",
            "\u2022 Juan Carlos Alonso, MD",
            "\u2022 Jos\u00e9 Alberto San Rom\u00e1n, MD",
            "Javier L\u00f3pez",
            "Pedro Mota",
            "Roman Arnold"
      ],
      "LocationContactPhone": [
            "034 91 426 5882"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Principal Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Principal Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator"
      ],
      "LocationCountry": [
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Hospital General Universitario Gregorio Mara\u00f1\u00f3n",
            "Hospital Clinico Universitario de Valladolid"
      ],
      "LocationState": [],
      "LocationStatus": [
            "Recruiting",
            "Not yet recruiting"
      ],
      "LocationZip": [
            "28007"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy."
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Hospital General Universitario Gregorio Mara\u00f1on"
      ],
      "OrgStudyId": [
            "FIBHGM-ECNC017-2010"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital General Universitario Gregorio Mara\u00f1\u00f3n"
      ],
      "OverallOfficialName": [
            "Francisco Fernandez Aviles, PhD"
      ],
      "OverallOfficialRole": [
            "Study Chair"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "March 2018"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Major adverse cardiac adverse events includes cerebral adverse events"
      ],
      "PrimaryOutcomeMeasure": [
            "Major adverse cardiac adverse events. SAEs and AEs.",
            "NYHA functional class.",
            "Incidence of complications with the use of NOGA XPTM catheters.",
            "Laboratory parameters including C-reactive protein an brain natriuretic peptide"
      ],
      "PrimaryOutcomeTimeFrame": [
            "change from enrollment( 1, 3, 6, 12, 18 and 24 months)",
            "Change from enrolment( 1, 3, 6, 12, 18, 24 months)",
            "Change from enrolment( 1, 3, 6, 12, 18, 24 months)",
            "Change from enrolment( 1, 3, 6, 12, 18, 24 months)"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2010-024406-35",
            "MIYOCYTE"
      ],
      "SecondaryIdDomain": [
            "MYOCYTE"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number",
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "include 36-item Short Form Survey(SF 36) and Minnesota Living UIT Heart Failure questionnaire"
      ],
      "SecondaryOutcomeMeasure": [
            "NYHA Functional Class",
            "Max.oxygen consumption(MVO2),functional capacity.",
            "Quality of life questionnaires",
            "Extension. of perfusion defects(MRI/SPECT).",
            "LVEF, ventricular vol.,wall motion score index(echocard./MRI/SPECT",
            "LVEF(left ventriculogram, electromech. mapping parameters(NOGA XPTM))"
      ],
      "SecondaryOutcomeTimeFrame": [
            "1, 3, 6, 12, 18, 24 months",
            "6,12,24 months",
            "6,12 and 24 months",
            "6 and 24 months",
            "6,12 and 24 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 2013"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "November 2016"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "October 8, 2013"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "December 21, 2012"
      ],
      "StudyFirstSubmitQCDate": [
            "October 7, 2013"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}